Business Wire

Separate Independent Studies Found that PREVENA™ Therapy Reduced Complications Following Breast Cancer Surgery and Breast Reconstruction

Jaa

KCI, an Acelity Company, announced today that recently published data stemming from two studies demonstrate that closed incision negative pressure therapy (ciNPT) with the PREVENA™ Incision Management System reduced postsurgical wound complication potential in patients recovering from oncological breast surgery and breast reconstruction, respectively.

One study titled, “The Impact of Closed Incision Negative Pressure Therapy on Postoperative Breast Reconstruction Outcomes,” showed that patients who received ciNPT with the PREVENA™ System had significantly lower rates of overall complications and returns to the operating room compared to those in the standard of care (SOC) for incision management after breast reconstruction post-mastectomy group. In addition, patients in the PREVENA™ Therapy group overall had a shorter mean time to complete removal of all drains than the SOC group, averaging 9.9 days versus 13.1, respectively.1

In a separate study titled, “Closed Incision Negative Pressure Therapy in Oncological Breast Surgery: Comparison with Standard Care Dressings,” researchers found that patients in the PREVENA™ Therapy group showed significantly lower postsurgical complication rates, demonstrating 4 percent in the PREVENA™ Therapy group versus 45 percent in the SOC group.2

“Minimizing the risk of complications for the patients in my care is of the utmost importance to me as a practicing plastic surgeon, and this recent data adds to the established body of evidence that demonstrates the ability of PREVENA™ Therapy to help preserve outcomes for breast reconstruction patients,” said Ron Silverman, M.D., F.A.C.S., Chief Medical Officer, KCI, an Acelity Company. “Further, this data has implications for lowering healthcare costs and improving quality and the patient experience as post-operative complications create a tremendous burden impacting patients, surgeons and payers. At KCI, we are dedicated to bringing to market innovations that address these needs supported by proven-real world results that improve patients’ lives.”

The American Cancer Society estimated that in 2017, there were more than 252,710 new invasive breast cancer cases in the United States. Breast reconstruction among women in the United States undergoing mastectomy has increased from 12 percent in 1998 to 36 percent in 2011.3 Postoperative infection remains the most common and likely the most feared complication from breast reconstruction surgery, which can often cost an additional $10,000 or more.4,5

Study Overviews

“The Impact of Closed Incision Negative Pressure Therapy on Postoperative Breast Reconstruction Outcomes:”

  • A single site, retrospective review of records for 356 adult female patients who underwent breast reconstruction post-mastectomy was conducted. Records were divided into two groups for comparative analysis: patients who received SOC versus patients who received ciNPT with the PREVENA™ Incision Management System for closed incision management post breast reconstruction.

“Closed Incision Negative Pressure Therapy in Oncological Breast Surgery: Comparison with Standard Care Dressings:”

  • In a study of 37 patients undergoing oncological breast surgery, 17 patients (25 surgeries) received ciNPT with the PREVENA™ Incision Management System and the remaining 20 patients (20 surgeries) had SOC.

Both studies were published in Plastic and Reconstructive Surgery - Global Open.

About PREVENA™ Incision Management System

The PREVENA™ System, launched in 2010, is the first disposable negative pressure system designed specifically for the management of closed surgical incisions. The system covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision. Please refer to the Instructions for Use for the PREVENA™ Systems for a complete list of appropriate uses, warnings, and precautions.

About Acelity, Inc.

Acelity, Inc. is a global advanced wound care company committed to developing innovative healing solutions for customers and patients across the care continuum. Its subsidiary, KCI, is a well trusted brand in advanced wound care. KCI’s solutions are available in more than 90 countries and deliver value through solutions by speeding healing. KCI is a leader in quality, safety and customer experience and is committed to advancing the science of healing, KCI sets the standard for leading advanced wound therapy innovation.

1 Gabriel A, Sigalove S, Sigalove N, Storm-Dickerson T, Rice J, Maxwell P, Griffin L. The impact of closed incision negative pressure therapy on postoperative breast reconstruction outcomes. Plast Reconstr Surg Glob Open. 2018 Aug; 6(8):e1880.

2 Ferrando PM, Ala A, Bussone R, Bergamasco L, Perinetti FA, Malan F. Closed incision negative pressure therapy in oncological breast surgery: Comparison with standard care dressings. Plast Reconstr Surg Glob Open. 2018;6(6):e1732.

3 American Cancer Society, “Breast Cancer Facts and Figures 2017-2018.” Retrieved from https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf.

4 Kim JY, Davila AA, Persing S et al. A meta-analysis of human acellular dermis and submuscular tissue expander breast reconstruction. Plast Reconstr Surg 2012;129:28-41.

5 Susman, Ed. Post-Mastectomy Breast Reconstruction and Complications Swell Costs. Oncology Times 2016; 38:3.

Contact information

Acelity
Maggie Fairchild
Corporate Communications
Phone: +1-210-330-2666
Email: maggie.fairchild@acelity.com
or
Jathan Tucker
Investor Relations
Phone: +1-210-255-6816
Email: jathan.tucker@acelity.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 12:07Tiedote

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 10:58Tiedote

Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs

Kalray Joins Autoware Foundation as Founding Premium Member14.12.2018 10:18Tiedote

Kalray (Euronext Growth Paris – ALKAL), a pioneer in processors for new intelligent systems, today announced it has joined the Autoware Foundation as a founding premium member. The formation of Autoware was formally announced on December 10, 2018 with a mission of facilitating the deployment of Autoware open-source projects enabling self-driving mobility. The Autoware Foundation creates synergies between corporate development and academic research, enabling autonomous driving technology for everyone. "We are glad to have the presence of Kalray as a premium member of the Autoware Foundation. Having highly efficient hardware solutions supporting autonomous driving software is instrumental to boost the deployment of Autoware in the market!" said Shinpei Kato, member of the Board of Directors for Autoware. Autonomous driving demands massive processing power, low power consumption and bulletproof safety and security to handle critical functions like AI processing, acceleration of perception

IDEMIA Provides Subscription Management Platform to dtac in Thailand to Offer eSIM Connected Watches to All Its Subscribers.14.12.2018 06:30Tiedote

IDEMIA, the global leader in Augmented Identity, has been selected by dtac, the leading mobile operator in Thailand, to offer connectivity on eSIM connected watches. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005934/en/ Credits : IDEMIA IDEMIA’s Subscription Management platform (or remote SIM provisioning) is the technology that remotely connects the embedded SIM of a smartwatch to dtac’s network without inserting a physical SIM card. Indeed, the IDEMIA Subscription Manager is a server which securely manages the lifecycle of mobile subscriptions and profiles for eSIM-ready consumer devices and wearables. This solution is compliant with the latest GSMA (Global System for Mobile Communications Association) standards to ensure global interoperability and, thanks to the scalability of the platform, the operator will be able to serve up to millions of customers during peak times. dtac subscribers now have the possibilit

CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer13.12.2018 20:46Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an additional indication to include rucaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. EC approval is anticipated in the first quarter of 2019. Once approved, Rubraca’s indication will expand beyond its initial Marketing Authorization in Europe granted in May 2018 for adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum

Dole Food Company Sells Fresh Cut Business in Sweden and Finland13.12.2018 20:00Tiedote

Dole Food Company, Inc., announced today an agreement to sell Saba Fresh Cuts AB and Saba Fresh Cuts OY to BAMA International. Saba Fresh Cuts AB—with production facility in Helsingborg Sweden—and Saba Fresh Cuts OY—with production facility in Espoo Finland—are producers of washed and ready-to-eat salads. The companies prepare and sell various fresh-cut salads and vegetables to the retail and foodservice industry in Sweden, Denmark, Finland, Germany and the Baltic States. The sale of Saba Fresh Cuts AB was a necessary condition of the European Commission’s approval of the investment by Total Produce into Dole in July 2018. “I am very pleased with the outcome of this sale in meeting the EU’s requirement,” said Mr. Johan Linden, President and Chief Executive Officer of Dole Food Company, “and I am confident that Saba Fresh Cuts will be in good hands under BAMA’s ownership.” "We are pleased to announce this agreement with Dole for Saba Fresh Cuts. Convenience products and ready-to-eat sal

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme